NYSE:ARMP
Armata Pharmaceuticals, Inc.
A cash-burn biopharma firm developing oncology assets with a current market cap supported primarily by paid-in capital rather than operational earnings.
Key Metrics
Investment Thesis
Bull Case
The company's paid-in capital of $279.4M provides a substantial runway to develop its pipeline before needing further dilution or debt financing. Successful clinical trials could unlock significant value through potential licensing deals and milestone payments from major pharmaceutical partners. The recent reduction in net loss suggests improving operational efficiency as the company transitions toward later-stage development.
Bear Case
With total liabilities of $134.5M against only $86.4M in total assets, the balance sheet is technically insolvent and heavily reliant on future equity raises. The lack of any revenue stream for five years creates a high risk of default if clinical programs fail or capital markets dry up. Investors are effectively betting on speculative drug development outcomes with no current cash generation to service debts or pay dividends.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals (ARMP) is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics for oncology and immunology. The company currently has no reported revenue but holds significant cash reserves funded by equity financing to support its early-stage drug development programs. With substantial liabilities from long-term operating leases, the firm relies heavily on future milestone payments and partnership deals to achieve profitability.
Analysis
Management Discussion
Despite a net profit improvement to -$18.9M in 2024 from -$69.0M the previous year, the company continues to report substantial operating losses driven by high general and administrative expenses of $13.2M. Cash flow from operations remains negative at -$37.6M while cash flow from financing provided a one-time boost of $35.0M, highlighting the current dependence on equity issuance rather than organic growth.
Industry Overview
The biotechnology sector is characterized by high failure rates in drug development and significant upfront capital requirements before any commercial revenue is generated. Companies often operate at a loss for years while conducting clinical trials, relying on venture capital, public markets, or strategic partnerships to fund operations. Regulatory hurdles and long approval timelines mean profitability can take over a decade even for successful therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $-5.5M | $-4.5M | $-5.2M |
| Gross Profit | $5.5M | $4.5M | $5.2M |
| Operating Expenses | $42.5M | $45.4M | $47.6M |
| Operating Income | $-36.9M | $-40.9M | $-42.4M |
| G&A | $7.4M | $11.6M | $13.2M |
| Stock-Based Comp | $3.1M | $938.0K | $2.9M |
| D&A | — | $972.0K | $1.3M |
| Depreciation | $892.0K | $1.0M | $1.3M |
| Other OpEx | $35.0M | $33.8M | $34.4M |
| Non-Operating Income | $29.0K | $40.8M | $23.5M |
| Interest Expense | $0 | — | — |
| Interest Income | $29.0K | $179.0K | — |
| Pre-Tax Income | $-36.9M | $-69.0K | $-18.9M |
| Income Tax | $0 | $69.0M | $0 |
| Continuing Ops | $-36.9M | $-69.0M | $-18.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-36.9M | $-69.0M | $-18.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-36.9M | $-69.0M | $-18.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $27.0M | $19.2M | $11.3M |
| Cash & Equivalents | $14.9M | $13.5M | $9.3M |
| Prepaid Expenses | $10.3M | $2.3M | $1.3M |
| Other Current Assets | $1.9M | $3.4M | $744.0K |
| Long-Term Assets | $68.8M | $79.2M | $75.1M |
| PP&E (Net) | $3.6M | $12.6M | $13.2M |
| Intangibles | $10.3M | $10.3M | $10.3M |
| Goodwill | $3.5M | $3.5M | $3.5M |
| Operating Leases | $43.0M | $44.7M | $41.7M |
| Other LT Assets | $8.4M | $8.2M | $6.5M |
| Total Assets | $95.8M | $98.4M | $86.4M |
| Current Liabilities | $24.9M | $16.5M | $48.2M |
| Accounts Payable | $1.7M | $1.6M | $766.0K |
| Current Leases | $17.0M | $9.5M | $4.4M |
| Other Current Liab | $6.2M | $5.4M | $43.1M |
| Long-Term Liabilities | $34.9M | $114.0M | $86.2M |
| LT Operating Leases | $31.8M | $28.6M | $27.7M |
| Other LT Liab | $3.1M | $85.4M | $58.5M |
| Total Liabilities | $59.8M | $130.4M | $134.5M |
| Shareholders' Equity | $36.1M | $-32.1M | $-48.0M |
| Paid-In Capital | $275.5M | $276.4M | $279.4M |
| Retained Earnings | $-239.8M | $-308.8M | $-327.7M |
| Total L&E | $95.8M | $98.4M | $86.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-36.9M | $-69.0M | $-18.9M |
| Non-Cash Adjustments | $-12.4M | $40.9M | $-6.3M |
| Working Capital Changes | $16.8M | $-19.3M | $-12.3M |
| Cash from Operations | $-32.5M | $-47.4M | $-37.6M |
| Capital Expenditures | $2.2M | $8.1M | $1.9M |
| Cash from Investing | $-2.2M | $-8.1M | $-1.9M |
| Cash from Financing | $44.0M | $54.0M | $35.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $9.3M | $-1.6M | $-4.5M |
| Beginning Cash | $11.5M | $20.8M | $19.2M |
| Ending Cash | $20.8M | $19.2M | $14.8M |
Frequently Asked Questions
How does Armata Pharmaceuticals, Inc. make money?
Oncology drug discovery and development; Immunology therapeutic pipelines; Strategic partnerships and licensing agreements for future revenue streams; Pre-commercial clinical stage research operations.
What are the main risks for ARMP?
Severe negative net income of $18.9M and a retained earnings deficit of $327.7M indicating unsustainable burn without new funding; Current liabilities of $48.2M significantly exceeding current assets of $11.3M creating liquidity pressure; Complete absence of revenue for five consecutive years increasing reliance on external capital markets.
What is ARMP's competitive advantage?
Specialized expertise in cancer biology and immune-oncology targets; Potential high-value milestone payments upon successful regulatory approvals; Low capital expenditure footprint relative to total asset base allowing lean operational scaling.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.